$XWEL
XWELL Inc Stock $xwel

$xwel Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000155837021015938 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$29.36M	$26.77M	$201.0K
YoY Change	9074.38%	13216.92%	-98.4%
Cost Of Revenue	$15.86M	$13.66M	$1.405M
YoY Change	552.8%	872.38%	-85.5%
Gross Profit	$13.50M	$13.11M	-$1.204M
YoY Change	-739.57%	-1188.46%	-142.39%
Gross Profit Margin	45.97%	48.96%	-599.0%
Selling, General & Admin	$9.849M	$5.196M	$4.368M
YoY Change	98.17%	18.96%	40.45%
% of Gross Profit	72.98%	39.65%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$659.0K	$852.0K	$1.424M
YoY Change	-50.45%	-40.17%	-2.47%
% of Gross Profit	4.88%	6.5%
Operating Expenses	$10.51M	$5.196M	$4.368M
YoY Change	66.79%	18.96%	-4.42%
Operating Profit	$2.987M	$7.057M	-$9.223M
YoY Change	-135.52%	-176.52%	433.12%
Interest Expense	-$317.0K	-$296.0K	-$120.0K
YoY Change	-1685.0%	146.67%	-84.62%
% of Operating Profit	-10.61%	-4.19%
Other Income/Expense, Net	-$42.00K	-$381.0K	-$47.00K
YoY Change	-103.36%	710.64%	-97.77%
Pretax Income	$1.813M	$6.682M	-$6.640M
YoY Change	-111.05%	-200.63%	38.91%
Income Tax	-$23.00K	$87.00K	$3.000K
% Of Pretax Income	-1.27%	1.3%
Net Earnings	$3.275M	$5.597M	-$6.110M
YoY Change	-120.89%	-191.6%	26.24%
Net Earnings / Revenue	11.16%	20.91%	-3039.8%
Basic Earnings Per Share		$0.05	-$0.10
Diluted Earnings Per Share	$30.49K	$0.05	-$0.10
COMMON SHARES
Basic Shares Outstanding	105.7M	105.5M	61.11M
Diluted Shares Outstanding		106.0M	61.11M

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.5M	$109.2M	$61.90M
YoY Change	17.49%	76.35%	2479.17%
Cash & Equivalents	$105.5M	$109.2M	$62.60M
Short-Term Investments
Other Short-Term Assets	$1.095M	$1.835M	$1.300M
YoY Change	-17.11%	41.15%	85.71%
Inventory	$1.763M	$2.040M	$600.0K
Prepaid Expenses	$1.047M	$1.787M
Receivables	$615.0K	$64.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$109.0M	$113.1M	$63.90M
YoY Change	18.74%	77.0%	1497.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.658M	$4.532M	$10.20M
YoY Change	60.01%	-55.57%	-47.42%
Goodwill
YoY Change
Intangibles	$3.732M	$2.725M
YoY Change	328.97%
Long-Term Investments
YoY Change
Other Assets	$2.810M	$2.502M	$2.000M
YoY Change	8.58%	25.1%	-31.03%
Total Long-Term Assets	$18.29M	$16.18M	$17.63M
YoY Change	61.06%	-8.24%	-40.64%
TOTAL ASSETS
Total Short-Term Assets	$109.0M	$113.1M	$63.90M
Total Long-Term Assets	$18.29M	$16.18M	$17.63M
Total Assets	$127.3M	$129.3M	$81.53M
YoY Change	23.4%	58.57%	141.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.535M	$8.700M	$8.200M
YoY Change	-25.2%	6.1%	5.13%
Accrued Expenses	$2.736M	$2.797M	$2.700M
YoY Change	-2.29%	3.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.584M	$5.653M	$2.800M
YoY Change	8.61%	101.89%
Total Short-Term Liabilities	$19.83M	$17.20M	$14.30M
YoY Change	47.12%	20.27%	83.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.100M
YoY Change	-100.0%	-100.0%	-40.38%
Other Long-Term Liabilities	$7.504M	$8.156M	$5.800M
YoY Change	8.75%	40.62%	-64.2%
Total Long-Term Liabilities	$7.504M	$8.156M	$8.900M
YoY Change	-19.31%	-8.36%	-58.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.83M	$17.20M	$14.30M
Total Long-Term Liabilities	$7.504M	$8.156M	$8.900M
Total Liabilities	$27.33M	$25.35M	$25.80M
YoY Change	20.07%	-1.73%	-22.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$395.3M	-$398.6M
YoY Change	-0.84%
Common Stock	$1.013M	$1.053M
YoY Change	7.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.73M	$96.03M	$55.70M
YoY Change
Total Liabilities & Shareholders Equity	$127.3M	$129.3M	$81.50M
YoY Change	23.4%	58.62%	141.84%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	$3.275M	$5.597M	-$6.110M
YoY Change	-120.89%	-191.6%	26.24%
Depreciation, Depletion And Amortization	$659.0K	$852.0K	$1.424M
YoY Change	-50.45%	-40.17%	-2.47%
Cash From Operating Activities	$8.594M	$7.781M	-$5.210M
YoY Change	-206.36%	-249.35%	410.78%
INVESTING ACTIVITIES
Capital Expenditures	-$2.784M	-$2.152M	-$2.130M
YoY Change	220.0%	1.03%	153.57%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.434M
YoY Change
Cash From Investing Activities	-$2.784M	$282.0K	-$2.130M
YoY Change	220.0%	-113.24%	153.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.429M	-1.428M	31.47M
YoY Change	-125.57%	-104.54%	1489.39%
NET CHANGE
Cash From Operating Activities	8.594M	7.781M	-5.210M
Cash From Investing Activities	-2.784M	282.0K	-2.130M
Cash From Financing Activities	-9.429M	-1.428M	31.47M
Net Change In Cash	-3.619M	6.635M	24.13M
YoY Change	-112.96%	-72.5%	20008.33%
FREE CASH FLOW
Cash From Operating Activities	$8.594M	$7.781M	-$5.210M
Capital Expenditures	-$2.784M	-$2.152M	-$2.130M
Free Cash Flow	$11.38M	$9.933M	-$3.080M
YoY Change	-257.81%	-422.5%	1611.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.15
	dei	Entity Central Index Key EntityCentralIndexKey	0001410428
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94058853
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105327379
CY2020Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.33
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34785
	dei	Entity Registrant Name EntityRegistrantName	XpresSpa Group, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4988129
	dei	Entity Address Address Line1 EntityAddressAddressLine1	254 West 31st Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	309-7549
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	XSPA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105662421
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109161000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89801000
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64000
CY2021Q3	us-gaap	Inventory Net InventoryNet	2040000
CY2020Q4	us-gaap	Inventory Net InventoryNet	657000
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1835000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1321000
CY2021Q3	us-gaap	Assets Current AssetsCurrent	113100000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	91779000
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	751000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	701000
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4532000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4161000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	870000
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2725000
CY2020Q4	us-gaap	Liabilities Liabilities	22762000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105327379
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94058853
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	1053000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	941000
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	493814000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	475709000
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398550000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398624000
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129277000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103133000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26767000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44371000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8062000
CY2021Q3	us-gaap	Cost Direct Labor CostDirectLabor	4277000
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5667000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3034000
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2502000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2588000
CY2021Q3	us-gaap	Assets Assets	129277000
CY2020Q4	us-gaap	Assets Assets	103133000
CY2021Q3	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	8724000
CY2020Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	6468000
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2797000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2797000
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	24000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	914000
CY2021Q3	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	5653000
CY2020Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	3298000
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17198000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13477000
CY2020Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2355000
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8156000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6930000
CY2021Q3	us-gaap	Liabilities Liabilities	25354000
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-283000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-220000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	96034000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	77806000
CY2021Q3	us-gaap	Minority Interest MinorityInterest	7889000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	2565000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103923000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80371000
CY2020Q3	us-gaap	Cost Direct Labor CostDirectLabor	514000
	us-gaap	Cost Direct Labor CostDirectLabor	7419000
	us-gaap	Cost Direct Labor CostDirectLabor	5480000
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1424000
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2750000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	50917000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-381000
CY2021Q3	xspa	Cost Of Occupancy CostOfOccupancy	587000
CY2020Q3	xspa	Cost Of Occupancy CostOfOccupancy	468000
	xspa	Cost Of Occupancy CostOfOccupancy	1511000
	xspa	Cost Of Occupancy CostOfOccupancy	2334000
CY2021Q3	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	8798000
CY2020Q3	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	423000
	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	16592000
	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	1737000
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	13662000
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	1405000
	us-gaap	Cost Of Revenue CostOfRevenue	25522000
	us-gaap	Cost Of Revenue CostOfRevenue	9551000
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	852000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2542000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3875000
CY2020Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2227000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	22000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	6319000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5196000
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4368000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14350000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10972000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	19710000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	9424000
	us-gaap	Costs And Expenses CostsAndExpenses	42436000
	us-gaap	Costs And Expenses CostsAndExpenses	30717000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7057000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9223000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1935000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22655000
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6000
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-120000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	31000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1856000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-47000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-830000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-389000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6682000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6640000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1136000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75817000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	79000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	6595000
	us-gaap	Profit Loss ProfitLoss	1057000
	us-gaap	Profit Loss ProfitLoss	-75839000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-6643000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	994000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75806000
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.15
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105531418
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61106894
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103950731
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35309004
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105957317
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61106894
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104301344
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35309004
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80371000
CY2021Q1	xspa	Cashless Exercise Of Warrants Into Common Stock Value CashlessExerciseOfWarrantsIntoCommonStockValue	17007000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1005000
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	998000
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-533000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	983000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1034000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	5597000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-6110000
	us-gaap	Net Income Loss NetIncomeLoss	74000
	us-gaap	Net Income Loss NetIncomeLoss	-74805000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	6595000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-6643000
	us-gaap	Profit Loss ProfitLoss	1057000
	us-gaap	Profit Loss ProfitLoss	-75839000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-52000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-63000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	33000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6543000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6625000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-808000
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-16000
CY2021Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	333000
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97892000
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	320000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	328000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-4730000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5000
CY2021Q2	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-133000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	93682000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	790000
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	29000
CY2021Q3	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	4307000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	6595000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-52000
CY2021Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	450000
CY2021Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	991000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103923000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2536000
CY2020Q1	xspa	Direct Offerings Of Registered Common Stock Value DirectOfferingsOfRegisteredCommonStockValue	4258000
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	135000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72000
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-10725000
CY2020Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	117000
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3739000
CY2020Q2	xspa	Direct Offerings Of Registered Common Stock Value DirectOfferingsOfRegisteredCommonStockValue	38397000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	424000
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	15000
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-58471000
CY2020Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	129000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29661000
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3363000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	470000
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2020Q3	xspa	Stock Issued During Period Value For Repayment Debt And Interest StockIssuedDuringPeriodValueForRepaymentDebtAndInterest	35000
CY2020Q3	xspa	Direct Offerings Of Registered Common Stock Value DirectOfferingsOfRegisteredCommonStockValue	31462000
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	18000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-6643000
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58371000
	us-gaap	Profit Loss ProfitLoss	1057000
	us-gaap	Profit Loss ProfitLoss	-75839000
	xspa	Fair Value Adjustment Of Warrants And Conversion Options FairValueAdjustmentOfWarrantsAndConversionOptions	50917000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2542000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3875000
	xspa	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	22000
	xspa	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	6319000
	us-gaap	Accretion Expense AccretionExpense	1070000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1162000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1568000
	xspa	Issuance Of Shares Of Common Stock For Repayment Of Debt And Interest IssuanceOfSharesOfCommonStockForRepaymentOfDebtAndInterest	497000
	xspa	Issuance Of Shares Of Preferred Stock For Repayment Of Debt And Interest IssuanceOfSharesOfPreferredStockForRepaymentOfDebtAndInterest	63000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-182000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	349000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	135000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	125000
	us-gaap	Share Based Compensation ShareBasedCompensation	2123000
	us-gaap	Share Based Compensation ShareBasedCompensation	966000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-716000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1385000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-74000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-890000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16926000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2650000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3099000
	xspa	Proceeds From Acquisition Of Variable Interest Entities ProceedsFromAcquisitionOfVariableInterestEntities	2434000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-519000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	376000
	xspa	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-3035000
	xspa	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-4286000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2713000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2156000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2231000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5967000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	380000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2372000
CY2021Q3	xspa	Number Of Airport NumberOfAirport	12
CY2021Q3	xspa	Number Of Airport Locations Operating NumberOfAirportLocationsOperating	11
CY2021Q3	xspa	Lease Concessions LeaseConcessions	585000
CY2020Q3	xspa	Lease Concessions LeaseConcessions	611000
	xspa	Lease Concessions LeaseConcessions	1568000
	xspa	Lease Concessions LeaseConcessions	1379000
	xspa	Lease Concessions LeaseConcessions	3600000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3479000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	17007000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	74125000
	xspa	Proceeds From Paycheck Protection Program ProceedsFromPaycheckProtectionProgram	5653000
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	500000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
	xspa	Proceeds From Funding Advance Net ProceedsFromFundingAdvanceNet	910000
	xspa	Payments Of Funding Advance Net PaymentsOfFundingAdvanceNet	819000
	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	133000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	450000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	333000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	117000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	991000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	129000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15779000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80362000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	36000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19410000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59960000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90502000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2635000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109912000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62595000
	us-gaap	Interest Paid InterestPaid	187000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	11000
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	15471000
	xspa	Conversion Of Stock Amount Converted Preferred Stock O Common Stock ConversionOfStockAmountConvertedPreferredStockOCommonStock	10000
	us-gaap	Stock Issued1 StockIssued1	12000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresSpa Group, Inc. (“XpresSpa Group or the “Company”) is a leading global travel health and wellness services holding company. XpresSpa Group currently has three reportable operating segments: XpresSpa™, XpresTest™, and Treat™ brand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresSpa has been a global airport retailer of spa services through its XpresSpa™ spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products (“XpresSpa”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Through XpresSpa Group’s subsidiary, XpresTest, Inc. (“XpresTest”), the Company launched XpresCheck™ Wellness Centers, also in airports. XpresCheck offers COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents. XpresTest has entered into managed services agreements (“the MSAs”) with Professional Corporation or Professional Limited Liability Companies (“PCs”) that provide health care services to patients. PCs pay XpresTest a monthly fee to operate in the XpresCheck Wellness Centers. Under the terms of the MSAs, the Company provides office space, equipment, supplies, non-licensed staff, and management services in return for a management fee. PCs arrange requisite COVID-19 and other medical diagnostic testing services</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;"> </span><span style="font-family:'Times New Roman','Times','serif';">through contracting with physicians and other medical professional providers to render these COVID-19 and other medical diagnostic testing services.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:8pt;text-decoration-color:#000000;visibility:hidden;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">XpresSpa Group is developing Treat™, a travel health and wellness brand that is positioned for a post-pandemic world. The Company anticipates delivering on-demand access to integrated healthcare through technology and personalized services, while leveraging XpresSpa’s historic travel wellness experience and XpresTest’s healthcare expertise under the XpresCheck brand. The Company sees this concept evolution as an opportunity in a new niche industry where XpresSpa Group can leverage technology in addition to its existing real estate and airport experience, providing travelers with peace of mind and access to integrated care. Over the long-term, we envision that digital channels will provide growth opportunities beyond the Company’s airport locations, achieved through subscription-based services that provide care and tools supporting travel health and wellness. Furthermore, the Company anticipates offering upstream content that can be monetized through affiliate revenue as well as curated retail through ecommerce through the Company’s dedicated website,</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> www.treatcare.com</i><span style="font-family:'Times New Roman','Times','serif';"> launched during the second quarter of 2021, later converting to </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">www.treat.com</i><span style="font-family:'Times New Roman','Times','serif';"> during the third quarter of 2021.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:8pt;text-decoration-color:#000000;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8-03 of Regulation S-X, and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as amended. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited annual financial statements but does not include all information required by GAAP for annual financial statements. The financial statements include the accounts of the Company, all entities that are wholly owned by the Company, and all entities in which the Company has a controlling financial interest as well as variable interest entities of which we are the primary beneficiary. All adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented have been reflected by the Company. Such adjustments are of a normal, recurring nature. The results of operations for the three and nine months periods ended September 30, 2021 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Recent Developments </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Effect of Novel Coronavirus (COVID-19) on Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In March 2020, the Company temporarily closed all global XpresSpa locations due to the categorization by local jurisdictions of the spa locations as “non-essential services.” A majority of the Company’s XpresSpa locations remain closed. The Company intends to reopen XpresSpa spa locations on a location-by-location basis and resume normal operations at such selected locations once restrictions are lifted and airport traffic returns to sufficient levels to support operations at a unit level. Between June 28<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>, 2021 and July 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup>, 2021, the Company re-opened its four top performing XpresSpa™ locations with modified hours and top selling services: Hartsfield-Jackson Atlanta International Airport (ATL) Concourse A, Dallas/Fort Worth International Airport (DFW) Concourse A, Charlotte Douglas International Airport (CLT) Concourse D, and Las Vegas McCarran International Airport (LAS) Concourse D. There are also three XpresSpa locations operating in Dubai International Airport in the United Arab Emirates as well as three XpresSpa locations operating in Schiphol Amsterdam Airport in the Netherlands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of 2021, the Company re-opened following XpresSpa™ locations with modified hours and top selling services:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">John F. Kennedy International Airport (JFK) on September 16, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Charlotte Douglas International Airport (CLT) Concourse A/B on September 20, 2021.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the fourth quarter of 2021 to date, the Company re-opened the following XpresSpa™ locations with modified hours and top selling services:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Hartsfield-Jackson Atlanta International Airport (ATL) Concourse C on October 14, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Orlando International Airport (MCO) on October 18, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Dallas/Fort Worth International Airport (DFW) Concourse D on October 23, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">William P. Hobby Airport (HOU) on November 8, 2021.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A majority of the domestic XpresSpa locations are operating approximately eight hours per day (compared to 16 hours pre-pandemic) with sales volumes about 30% to 60% of pre-pandemic levels. The Company implemented a price increase in mid-October and is planning to test some new touchless massage services and new retail items during the fourth quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company will re-evaluate each airport on a month-by-month basis as well as review continued learnings as the portfolio is re-activated. An additional two XpresSpa reopenings are planned for the remainder of the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the beginning of that temporary closure, the Company successfully launched its <span style="background-color:#ffffff;">XpresCheck™ Wellness Centers, offering such testing services, as described above and below.</span> Also, the Company continues to evaluate alternative testing protocols and work in partnership with airlines for safe travels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While management has used all currently available information in assessing its business prospects, the ultimate impact of the COVID-19 pandemic and the Company’s XpresCheck™ Wellness Centers on its results of operations, financial condition and cash flows remains uncertain. The success or failure of the Company’s XpresCheck™ Wellness Centers could also have a material effect on the Company’s business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">XpresCheck™ Wellness Centers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Through the Company’s XpresCheck™ Wellness Centers and under the terms of the MSAs with physicians’ practices, the Company offers testing services from the Company’s 14 XpresCheck™ Wellness Centers at 12 Airports in 11 states to airline employees, contractors, concessionaire employees, TSA officers and U.S. Customs and Border Protection agents, as well as the traveling public. The Company has entered into MSAs with professional medical service entities that provide healthcare services to patients. Under the terms of the MSAs, XpresTest provides office space, equipment, supplies, non-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">licensed staff, and management services to be used for the purpose of COVID-19 and other medical diagnostic testing in return for a management fee. Since December 31, 2020, the Company announced the opening of the following XpresCheck™ Wellness Centers to provide diagnostic COVID-19 testing:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On January 12, 2021, the Company opened its second XpresCheck™ Wellness Center at Boston’s Logan International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On January 20, 2021, the Company announced the opening of an XpresCheck™ Wellness Center at Salt Lake City International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">On February 16, 2021, the Company announced the opening of an XpresCheck™ Wellness Center of the Company’s second XpresCheck™ testing facility at Newark Liberty International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On March 8, 2021, the Company announced the opening of an XpresCheck™ Wellness Center at Houston George Bush Intercontinental Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On March 15, 2021, the Company announced the opening of XpresCheck™ Wellness Centers at Dulles International and Reagan National Airports in Virginia, containing </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">nine</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms, respectively, to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On April 8, 2021, the Company announced the opening of an XpresCheck™ Wellness Center at Seattle-Tacoma International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">eight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">On April 21, 2021, the Company announced the opening of an XpresCheck™ Wellness Center at San Francisco International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">nine</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">On October 13, 2021, the Company opened an XpresCheck™ Wellness Center at Hartsfield-Jackson Atlanta International Airport (ATL) Concourse E. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Airport Rent Concessions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has received rent concessions from landlords on a majority of our leases, allowing for the relief of minimum guaranteed payments in exchange for percentage-of-revenue rent or providing relief from rent through payment deferrals. Currently, the periods of relief from these payments, which began in March 2020, range from <span style="-sec-ix-hidden:Hidden_zonwJUzyWkmSVS_4-zsk5Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to twenty-eight months. The Company received minimum guaranteed payment concessions of approximately $585 and $611 in the three months ended September 30, 2021 and 2020, respectively, $1,568 and $1,379 in the nine months ended September 30, 2021 and 2020, respectively, and $3,600 in the eighteen months ended September 30, 2021. The Company expects to realize additional rent concessions while a majority of its spas remain closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash and cash equivalents, excluding restricted cash, of $109,161, total current assets of $113,100, total current liabilities of $17,198 and positive working capital of $95,902, compared to a positive working capital of $78,302 as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the nine months ended September 30, 2021, holders of the Company’s December 2020 Investor Warrants, December 2020 Placement Agent Warrants and December 2020 Placement Agent Tail Fee Warrants exercised a total of 11,223,529 warrants for common shares. The Company received gross proceeds of approximately $19,161. In accordance with the placement agent agreements with H.C. Wainwright & Co., LLC and Palladium, the Company paid cash fees of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$2,154 and issued 842,588 warrants to H.C. Wainwright & Co., LLC at an exercise price of $2.125 per share and 325,500 warrants to Palladium at an exercise price of $1.70 per share. See <i style="font-style:italic;">Note 11. Stockholders’ Equity</i> for related discussion. </p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021Q3	xspa	Number Of Wellness Center NumberOfWellnessCenter	14
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109161000
CY2021Q3	us-gaap	Assets Current AssetsCurrent	113100000
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17198000
CY2021Q3	xspa	Working Capital WorkingCapital	95902000
CY2020Q4	xspa	Working Capital WorkingCapital	78302000
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6110000
CY2021Q4	xspa	Revenue Contract Amount Not Yet Recognized RevenueContractAmountNotYetRecognized	2000000
CY2021Q4	xspa	Revenue Recognition After Milestone Reached RevenueRecognitionAfterMilestoneReached	1500000
CY2021Q4	xspa	Percentage Of Revenue Recognition After Milestone Reached PercentageOfRevenueRecognitionAfterMilestoneReached	0.75
	xspa	Presentation Presentation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;"> (e) Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certain balances in the 2020 consolidated financial statements have been reclassified to conform to the presentation in the 2021 condensed consolidated financial statements, primarily the classification and presentation of deferred revenue on the condensed consolidated balance sheet.</p>
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5597000
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6110000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	74000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-74805000
	xspa	Deemed Dividend On Series D Warrants DeemedDividendOnSeriesDWarrants	945000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5597000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	74000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75750000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105531418
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61106894
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103950731
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35309004
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.15
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5597000
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6110000
CY2020Q4	us-gaap	Credit And Debit Card Receivables At Carrying Value CreditAndDebitCardReceivablesAtCarryingValue	7000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109912000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	74000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-75750000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105957317
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61106894
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104301344
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35309004
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.15
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41335926
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21962979
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41411212
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21962979
CY2021Q3	us-gaap	Cash Cash	106384000
CY2020Q4	us-gaap	Cash Cash	88636000
CY2021Q3	xspa	Currency Other Than Us Dollars CurrencyOtherThanUsDollars	2274000
CY2020Q4	xspa	Currency Other Than Us Dollars CurrencyOtherThanUsDollars	1158000
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	751000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	701000
CY2021Q3	us-gaap	Credit And Debit Card Receivables At Carrying Value CreditAndDebitCardReceivablesAtCarryingValue	503000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90502000
CY2021Q3	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	106120000
CY2020Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	88556000
CY2021Q3	xspa	Cash Held In Overseas Accounts CashHeldInOverseasAccounts	2274000
CY2020Q4	xspa	Cash Held In Overseas Accounts CashHeldInOverseasAccounts	1158000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2440000
CY2021Q3	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	890000
CY2020Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	2221000
CY2021Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	396000
CY2020Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	306000
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1787000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1135000
CY2021Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	48000
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	186000
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1835000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1321000
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5436000
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	534000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	551000
CY2021Q3	xspa	Accrued Liability For Unredeemed Gift Cards AccruedLiabilityForUnredeemedGiftCards	495000
CY2020Q4	xspa	Accrued Liability For Unredeemed Gift Cards AccruedLiabilityForUnredeemedGiftCards	495000
CY2021Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	298000
CY2021Q3	xspa	Other Accrual Current OtherAccrualCurrent	171000
CY2020Q4	xspa	Other Accrual Current OtherAccrualCurrent	161000
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	504000
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	294000
CY2021Q3	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	8724000
CY2020Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	6468000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4188000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1463000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2725000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2033000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1163000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	870000
CY2021Q3	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	95000
CY2020Q3	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	603000
	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	300000
	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	1742000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	192000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1118000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	786000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	629000
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2725000
CY2021Q3	xspa	Lease Concessions LeaseConcessions	585000
CY2020Q3	xspa	Lease Concessions LeaseConcessions	611000
	xspa	Lease Concessions LeaseConcessions	1568000
	xspa	Lease Concessions LeaseConcessions	1379000
	xspa	Lease Concessions LeaseConcessions	3600000
	us-gaap	Operating Lease Payments OperatingLeasePayments	3189000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1074000
	xspa	Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability	-3673000
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M7D
	xspa	Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability	-811000
	xspa	Right Of Use Asset Surrendered In Exchange For Termination Of Operating Lease Liability RightOfUseAssetSurrenderedInExchangeForTerminationOfOperatingLeaseLiability	9000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	986000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3551000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3071000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2545000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1760000
CY2021Q3	xspa	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1526000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13439000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2486000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10953000
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1007
CY2021Q3	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	185000
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	399000
CY2020Q3	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	278000
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	1074000
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	51000
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	45000
	us-gaap	Variable Lease Cost VariableLeaseCost	262000
	us-gaap	Variable Lease Cost VariableLeaseCost	468000
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	5653000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	5653000
CY2021Q3	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	15000000
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	250000
CY2021Q3	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	250000
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	450000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	819000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	470000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2152000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	496000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1353888
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1668297
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8334
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	183230
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.61
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2830621
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.63
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	858905
	xspa	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue	2.63
	xspa	Effective Income Tax Rate Global Operations EffectiveIncomeTaxRateGlobalOperations	0.0013
	xspa	Effective Income Tax Rate Discontinued Operations EffectiveIncomeTaxRateDiscontinuedOperations	0
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	79000
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
	xspa	Number Of Individuals Joined Case NumberOfIndividualsJoinedCase	415
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26767000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7057000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9223000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44371000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8062000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1935000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22655000
CY2021Q3	us-gaap	Assets Assets	129277000
CY2020Q3	us-gaap	Assets Assets	81529000

Files In Submission

Name	View Source	Status
0001558370-21-015938-index-headers.html	Edgar Link	pending
0001558370-21-015938-index.html	Edgar Link	pending
0001558370-21-015938.txt	Edgar Link	pending
0001558370-21-015938-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xspa-20210930.xsd	Edgar Link	pending
xspa-20210930x10q.htm	Edgar Link	pending
xspa-20210930x10q_htm.xml	Edgar Link	completed
xspa-20210930xex31d1.htm	Edgar Link	pending
xspa-20210930xex31d2.htm	Edgar Link	pending
xspa-20210930xex32.htm	Edgar Link	pending
xspa-20210930_cal.xml	Edgar Link	unprocessable
xspa-20210930_def.xml	Edgar Link	unprocessable
xspa-20210930_lab.xml	Edgar Link	unprocessable
xspa-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XWEL
XWELL Inc Stock $xwel

2021 Q4 Form 10-Q Financial Statement

#000155837021015938 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XWEL XWELL Inc Stock $xwel

2021 Q4 Form 10-Q Financial Statement

#000155837021015938 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XWEL
XWELL Inc Stock $xwel